stockrowPacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
- Revenue
- +5.52%
- EPS
- +7.69%
- Free cash flow
- −102.0%
- Total debt
- −0.29%
Quarter to September 2026, against a year earlier
Follow PACB
Alert me
Pacific Biosciences of California, Inc. (PACB) EV/Sales
As of 5 November 2026, Pacific Biosciences of California, Inc. (PACB) trades at a EV/Sales of 7.5×. Over the past ten years it has ranged from 1.8× (March 2018) to 104× (February 2021); the current reading is higher than 56% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.8× | 17.51% |
| FY2024 | 4.9× | (63.29%) |
| FY2023 | 13.4× | (9.65%) |
| FY2022 | 14.9× | (51.84%) |
| FY2021 | 30.9× | (39.18%) |
| FY2020 | 50.7× | 493.92% |
| FY2019 | 8.5× | (26.34%) |
| FY2018 | 11.6× | 341.40% |
| FY2017 | 2.6× | (28.37%) |
| FY2016 | 3.7× | (63.22%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 7.3× | 25.57% |
| Jun 2026 | 5.8× | 20.78% |
| Mar 2026 | 4.8× | (16.60%) |
| Dec 2025 | 5.8× | 22.44% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INMD InMode Ltd. compare | 0.8× |
| AHCO AdaptHealth Corp. compare | 0.8× |
| VREX VAREX IMAGING compare | 1.2× |
| QDEL QuidelOrtho Corporation compare | 1.4× |
| BVS Bioventus Inc. compare | 1.6× |
| CTKB Cytek Biosciences, Inc. compare | 2.2× |
| KIDS OrthoPediatrics Corp. compare | 3.1× |
| BBNX Beta Bionics, Inc. compare | 3.8× |
| PACB Pacific Biosciences of California, Inc. | 7.5× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)